Core Insights - Elicio Therapeutics is hosting a virtual KOL event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic ductal adenocarcinoma, highlighting the significant unmet medical need in this area [1][2] Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, particularly mKRAS-positive pancreatic and colorectal cancers [8] - The company aims to leverage its proprietary AMP technology to create effective off-the-shelf vaccines, enhancing the education and activation of cancer-specific T cells [8][11] Product Pipeline - Elicio's lead product candidate, ELI-002, is an AMP-powered therapeutic vaccine targeting mKRAS-driven cancers, currently in a randomized Phase 2 trial for adjuvant treatment of PDAC [2][9] - ELI-002 has shown promising results in earlier studies, with a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the full study population [8] - The company plans to expand ELI-002's application to other mKRAS-positive cancers, including lung cancer [8][10] Technology Platform - Elicio's AMP platform is designed to deliver immunotherapeutics directly to lymph nodes, potentially enhancing immune responses compared to conventional therapies [11][12] - The platform has demonstrated the ability to engage lymph nodes specifically, driving therapeutic immune responses of increased magnitude and durability in preclinical models [11][12]